濮阳东方医院看男科评价比较好濮阳东方男科医院割包皮手术安全不,濮阳东方医院治疗阳痿怎么收费,濮阳东方妇科医院评价好专业,濮阳东方男科技术非常哇塞,濮阳东方妇科医院评价怎么样,濮阳东方医院治早泄价格比较低,濮阳东方医院技术很好

GENEVA, Aug. 12 (Xinhua) -- 18 people seeking treatment at hospitals in Somalia had been confirmed cholera positive through laboratory tests, the Geneva based World Health Organization (WHO) said on Friday.The 18 positive cases were detected out of 30 stool samples collected from patients seeking treatment at hospitals for acute watery diarrhea, a symptom that could result from cholera, WHO spokesperson Tarek Jasarevic told reporters.All confirmed cases, including residents of Mogadishu district and those among internally displaced persons (IDPs), were said to be tested positive for the Vibrio cholera serotype "inaba", which had been the predominant serotype in Somalia for the past three years."These results are an alarming reminder of the critical situation in Mogadishu and other parts of Southern, Central Somalia, (which are) still experiencing drought, population displacement and conflict," Jasarevic said.WHO has reported a dramatic increase of acute watery diarrhea cases in Somalia.In June and July alone, 1,633 acute watery diarrhea cases had been registered in Banadir Hospital, Mogadishu, representing 38 percent of all reported cases in 2011, and a sharp rise comparing with the same period last year.The United Nations public health arm said the situation was related to poor sanitation and limited access to safe water in numerous informal IDP settlements and a limited capacity of existing health partners to access those settlements and provide essential health services.In addition, the high number of malnourished children due to the ongoing famine increased the susceptibility to waterborne diseases.

CANBERRA, Aug. 29 (Xinhua) -- An Australia report released on Monday draws a direct link between inaction on climate change and long-term social and mental health problems.The Climate Institute report, A Climate of Suffering: The Real Cost of Living with Inaction on Climate Change, points that in the wake of extreme weather in Australia, such as cyclones and droughts, there is an increase in depression, anxiety, post- traumatic stress and substance abuse.As many as one in five people reported "emotional injury, stress and despair" in the wake of these events.The report also warns continuing catastrophic weather events are creating anxiety and insecurity for children at levels not seen since the Cold War.It claims one in 10 children of primary school age showed symptoms of post-traumatic stress disorder after Cyclone Larry in 2006.According to Professor Ian Hickie, from the Brain & Mind Institute, regional and remote communities are most vulnerable to the impact of climate change.He said a recent study of rural New South Wales where, following the long drought, self-harm and suicide rose by up to eight percent."I think what we are seeing now is a much more significant counting of not just the short-term costs and reactions but the longer-term costs, the loss of community cohesion and that being essential to people's long-term mental health," Professor Hickie."The drought was a particularly instructive event for everyone in Australia and we saw a lot of focus for the first time on the mental health effects, particularly suicides in rural families, the effect on rural communities of prolonged examples of weather change," Hickie said.Climate Institute chief executive John Connor said that not only did natural disasters cost taxpayers about nine billion U.S. dollars last year, but there are also damaging Australia's social fabric.He said that with Australian regions increasingly exposed to extreme weather, recognizing and managing the risks of climate change is essential, and it is an insurance policy to protect Australia's communities.The study came as the political and social debate over Australian federal government's proposed carbon tax intensifies.In 2007, a report by the Commonwealth Scientific and Industrial Research Organization (CSIRO) projected the effects of various greenhouse gas emission scenarios for 2030, 2050 and 2070.It said droughts were likely to become more frequent, fire danger was set to increase and tropical cyclones were likely to become more intense.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

BEIJING, July 11 (Xinhuanet) -- U.S. federal government officially announced that it denied the medical use of marijuana."Department of Health and Human Services concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision," U.S. Department of Justice declared Friday.The announcement will keep marijuana in the classification of dangerous, addictive drug as heroin.The decision comes almost nine years after medical marijuana advocates asked the government to reclassify marijuana, as its therapeutic effectiveness in treating some diseases and relieving pain of patients.Joe Elford, the chief counsel for Americans for Safe Access (ASA), said he was not surprised by the government's disapproval."It is clearly motivated by a political decision that is anti-marijuana," He noted.This is the third petition to reclassify marijuana has failed to be approved. The former two were filed in 1972 and in 1995, respectively.